Kyverna Therapeutics (NASDAQ:KYTX) Earns Buy Rating from HC Wainwright

Posted by Francis Steltz on Jun 3rd, 2026

Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $25.00 price objective on the stock. HC Wainwright’s price objective would indicate a potential upside of 218.07% from the company’s previous close.

Several other equities analysts have also recently issued reports on KYTX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Friday, March 27th. JPMorgan Chase & Co. decreased their price objective on Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday, May 13th. Finally, Wall Street Zen cut Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $30.00.

View Our Latest Stock Report on Kyverna Therapeutics

Kyverna Therapeutics Trading Down 0.5%

Kyverna Therapeutics stock traded down $0.04 during midday trading on Wednesday, reaching $7.86. 236,253 shares of the stock traded hands, compared to its average volume of 871,952. The company has a 50-day simple moving average of $9.03 and a two-hundred day simple moving average of $8.52. Kyverna Therapeutics has a 12-month low of $2.52 and a 12-month high of $13.67. The firm has a market cap of $477.81 million, a PE ratio of -2.40 and a beta of 1.95. The company has a current ratio of 8.15, a quick ratio of 8.15 and a debt-to-equity ratio of 0.13.

Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.09. Research analysts expect that Kyverna Therapeutics will post -2.81 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kyverna Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Public Employees Retirement System of Ohio purchased a new stake in Kyverna Therapeutics during the third quarter worth approximately $28,000. Grey Ledge Advisors LLC acquired a new position in Kyverna Therapeutics during the first quarter worth approximately $86,000. EntryPoint Capital LLC acquired a new position in Kyverna Therapeutics during the fourth quarter worth approximately $94,000. Phoenix Wealth Advisors increased its position in Kyverna Therapeutics by 17.1% during the fourth quarter. Phoenix Wealth Advisors now owns 12,300 shares of the company’s stock worth $116,000 after buying an additional 1,800 shares during the period. Finally, Ameriprise Financial Inc. acquired a new position in Kyverna Therapeutics during the third quarter worth approximately $77,000. Hedge funds and other institutional investors own 18.08% of the company’s stock.

Kyverna Therapeutics Company Profile

(Get Free Report)

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.